Welcome to our dedicated page for 111 news (Ticker: YI), a resource for investors and traders seeking the latest updates and insights on 111 stock.
111, Inc. reports on a China-based, tech-enabled healthcare platform that connects consumers, pharmacies and healthcare partners through online and offline channels. The company’s recurring updates cover its B2B pharmaceutical sourcing platform, B2C online retail pharmacy activity, internet hospital services through 1 Clinic, and cloud-based services for offline pharmacies.
Company news also focuses on unaudited financial results, gross segment profit, operating expenses, cash flow, B2B gross margin trends and the transition toward an asset-light fulfillment partnership model. Other recurring topics include digital tools, supply-chain efficiency, drug commercialization services and Nasdaq ADR listing compliance matters.
On March 14, 2022, 111, Inc. (NASDAQ: YI) entered a strategic partnership with Shenzhen BGI Co., Ltd. to distribute SARS-CoV-2 Virus Antigen Detection Kits through its online pharmacy, 1 Pharmacy. This collaboration will make 1 Pharmacy the first online platform in China to offer these kits, starting pre-sales this week. This initiative aims to enhance epidemic prevention efforts across China by providing better access to testing resources directly to consumers via a digital platform.
On February 23, 2022, 111, Inc. (NASDAQ: YI) signed a strategic cooperation agreement with Xi'an Beilin Pharmaceutical Co., Ltd. This collaboration aims to enhance digital marketing and expand market access for Chinese patent medicines. Both companies will leverage their strengths to integrate resources, focusing on big data application and brand building. The partnership is expected to create new growth opportunities and improve accessibility for high-quality healthcare products in China.
111, Inc. (NASDAQ: YI) announced it will report its fourth quarter and fiscal year 2021 unaudited financial results on March 17, 2022, before the U.S. market opens. A conference call will follow at 7:30 AM ET on the same day. Participants must register in advance to receive dial-in information. 111, Inc. is a leading tech-enabled healthcare platform in China, providing access to pharmaceutical products and online healthcare services through its platforms including 1 Pharmacy and 1 Clinic.
111, Inc. (NASDAQ: YI) reported its Q3 2021 results, achieving net revenues of RMB3.35 billion (US$519.3 million), a 41.6% increase year-over-year. Service revenue surged 106%, with B2B services growing 336%. Gross profit rose 85% to a gross margin of 5.0%, driven by a 145% increase in B2B gross profit. Despite significant growth, the company faced a net loss of RMB165.8 million (US$25.7 million), up from RMB111.2 million last year. Looking ahead, Q4 revenues are expected to grow 30% to 40% year-over-year, projected to reach RMB3.44 billion to RMB3.70 billion.
Summary not available.
111, Inc. (NASDAQ: YI) will release its unaudited financial results for Q3 2021 on November 19, 2021, before U.S. market open. A conference call is scheduled at 7:30 AM ET on the same day, with registration required for participation. 111, Inc. operates a tech-enabled healthcare platform in China, connecting patients with medicines and healthcare services. The company runs an online retail pharmacy and an internet hospital, among other services, enhancing access to healthcare for consumers.
111, Inc. (NASDAQ: YI) has announced a strategic partnership with Chugai Pharma China to advance healthcare in China through innovative digital solutions. This collaboration aims to establish a 'SMART Healthcare City' concept, enhancing the treatment accessibility for chronic diseases. As the first e-commerce company to form such a partnership with Chugai, 111 will leverage its technological strengths to improve healthcare delivery. Both companies intend to align with China's 'Healthy China 2030' initiative, which targets comprehensive chronic disease management for better patient outcomes.
111, Inc. (NASDAQ: YI) announced its participation in the Cantor Global Healthcare Conference, taking place virtually from September 27-30, 2021. Senior VP Tiffany ZhuGe will present an update on the Company and engage in one-on-one meetings with investors on September 27, 2021, at 4:40 PM ET. A live and archived webcast will be accessible on the Company’s Investor Relations website. 111, Inc. focuses on digitally connecting patients with healthcare services in China, providing a wide array of pharmaceutical and online healthcare services through its various platforms.
111, Inc. (NASDAQ: YI) announced a $10 million share repurchase program, which will be executed over the next twelve months to enhance shareholder value. The buyback will provide the company with flexibility to repurchase shares at prevailing market prices through various transactions. This strategic move is expected to positively impact the stock price and reflect the company's confidence in its future performance. The repurchases will be funded from the existing cash balance, showcasing the company's commitment to maximizing shareholder returns.
111, Inc. (NASDAQ: YI) announced an expansion of its partnership with Bayer Healthcare, enhancing their collaboration on drug commercialization in China. Building on their initial 2020 agreement, the companies will now cover more therapeutic areas, including diabetes and oncology, while leveraging 111's technology and extensive pharmacy network to improve patient education and outreach. Moreover, a digital content portal will be developed for online pharmacist training. This partnership aims to modernize healthcare delivery in China, offering a more integrated healthcare solution.